• Second-generation Allergen Immunotherapy based on Anergis Contiguous Overlapping Peptides (COP) linked to Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch pollen allergy
  • Results of the study are expected in Q1 2020

ANTONY, France, and EPALINGES, Switzerland, October 17th, 2019 - Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), today announced the start of a new research study to evaluate the effects of second-generation COP allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.

This research collaboration combines the longstanding know-how of Stallergenes Greer in AIT with the ultra-fast AIT approach developed by Anergis and its partner Mymetics, namely the second-generation of COP allergen immunotherapy based on Anergis COPs and Mymetics virosomes (COP-Virosomes).

In 2018, Anergis and Mymetics reported that the COP-Virosomes were able to elicit a strong boost in TH1 antibody response without any IgE response. Stallergenes Greer will now test COP-Virosomes in an in-house therapeutic model of birch pollen allergy. This model has been shown as having predictive value towards the clinical efficacy for AIT candidates.

“We are excited to launch this new study and eager to evaluate the potential of COP-virosomes as a breakthrough AIT treatment of the future. The Stallergenes Greer therapeutic model mimics specific immune responses to birch pollen from allergic individuals and should assess evidence of COP-virosomes potential”, said Vincent Charlon, CEO of Anergis.

“On the basis of the results of the 2018 preclinical program, Stallergenes Greer sees great potential for second generation COP allergy treatments and we look forward to the results of this study as it may well open new areas of innovation for Stallergenes Greer and improve the quality of life of patients by reducing treatment lengths” concluded Amer Jaber, Executive VP Operations Europe and President of Stallergenes SAS.




  • Biopôle Building SC-A
    Route de la Corniche 4
    CH-1066 Epalinges
  • Email:

This website uses cookies to ensure you get the best experience on our website.